Background. The American College of Surgeons Oncology Group Z1031 trial demonstrated that neoadjuvant endocrine therapy (NET) increased breast-conserving surgery (BCS) rates for postmenopausal patients with clinical tumor stage 2-4c estrogen receptor-positive breast cancer. We evaluated national trends in NET use in relation to the conduct of the Z1031 trial and the impact of NET on the rates of BCS. Methods. Using the National Cancer Data Base (NCDB), we identified all cT2-4c hormone receptor (HR)-positive breast cancer patients age C50 years from 2004 to 2012. The time intervals of pre-Z1031 (2004-2006), during Z1031 (2007-2009), and post-Z1031 (2010-2012) were examined, and adjusted analyses were performed using multivariable logistic regression. Results. Of 77,272 patients, 2294 (3.0 %) received NET. Clinical T-stage distribution was 66,885 (86.6 %) for cT2, 7318 (9.5 %) for cT3, and 3069 (4.0 %) for cT4a-c. A small but statistically significant increase in NET use was noted, from 2.7 % pre-Z1031 to 3.2 % post-Z1031; the adjusted odds ratio (OR) for NET was 1. The use of endocrine therapy in the neoadjuvant setting was initially explored in Europe and is still more commonly used in Europe compared with the US. Two large international studies conducted in Europe were the P024 trial and the IMPACT trial. The P024 trial compared neoadjuvant letrozole with tamoxifen in T2-4c hormone receptor (HR)-positive breast cancer, and showed that letrozole was superior to tamoxifen in overall response rates and rates of breast conservation in women who were not eligible for breast-conserving surgery (BCS).
versus pre-Z1031. NET use varied by clinical T stage, increasing from 1.8 % pre-Z1031 to 2.4 % post-Z1031 in cT2 patients (p \ 0.001) and from 6.3 % pre-Z1031 to 7.4 % post-Z1031 in cT3 patients (p = 0.02). Patients receiving NET were more likely to undergo BCS compared with patients undergoing primary surgery (46.4 vs. 43.9 %; p = 0.02) with an adjusted OR of 1.60 (95 % CI 1.46-1.75; p \ 0.001). Conclusions. NET use has increased slowly since the Z1031 trial; however, overall use remains low. NET significantly increased the rates of BCS in patients with HRpositive clinical T2-4c breast cancer. Clinicians should consider NET use for patients with HR-positive breast cancer interested in BCS.
The use of endocrine therapy in the neoadjuvant setting was initially explored in Europe and is still more commonly used in Europe compared with the US. Two large international studies conducted in Europe were the P024 trial and the IMPACT trial. The P024 trial compared neoadjuvant letrozole with tamoxifen in T2-4c hormone receptor (HR)-positive breast cancer, and showed that letrozole was superior to tamoxifen in overall response rates and rates of breast conservation in women who were not eligible for breast-conserving surgery (BCS). 1 The IMPACT trial compared neoadjuvant tamoxifen, anastrozole, and the combination of tamoxifen and anastrozole in postmenopausal women with HR-positive breast cancer. Similar response rates were observed across the three arms, but higher rates of breast conservation with anastrozole were noted compared with tamoxifen. 2 These trials showed that aromatase inhibitors were associated with better response rates compared with tamoxifen as neoadjuvant therapy. They also showed that neoadjuvant endocrine therapy (NET) is a well-tolerated, reasonable treatment option for strongly HR-positive breast cancer patients who are interested in breast conservation. Similar to neoadjuvant chemotherapy, NET can downstage tumors and, importantly, also provides information on the tumors' endocrine responsiveness.
The American College of Surgeons Oncology Group (ACOSOG) Z1031 trial was a randomized, phase II NET trial comparing response rates between three aromatase inhibitors conducted in the US. A total of 377 postmenopausal women with clinical stage II or III estrogen receptor (ER)-positive breast cancer were enrolled from 2007 to 2009. Eligible patients were randomized to exemestane 25 mg daily, letrozole 2.5 mg daily, or anastrozole 1 mg daily for 16-18 weeks prior to surgery. The overall clinical response rate was 69 % (258/374), with no differences across the three aromatase inhibitors. 3 Furthermore, 51.5 % (84/163) of patients who were deemed by the surgeon to require mastectomy prior to therapy were able to successfully undergo BCS after treatment with NET. ACOSOG Z1031 results were initially presented at the American Society of Clinical Oncology Annual Meeting in 2010 and published in the Journal of Clinical Oncology in 2011. 3 The goal of our study was to assess whether the results of the Z1031 trial have impacted clinical practice in the US. We evaluated national trends in the use of NET in the years before and after the release of trial results, as well as the impact of NET on rates of BCS in the US using data from the National Cancer Data Base (NCDB).
MATERIALS AND METHODS

Study Design
The NCDB is a clinical oncology database jointly sponsored by the American College of Surgeons and the American Cancer Society. It is sourced from a hospitalbased registry collected in more than 1500 commission on cancer-accredited facilities and represents approximately 70 % of newly diagnosed cancer cases in the US.
The NCDB was queried from 2004 to 2012 for breast cancer patients C50 years of age with tumor stage cT2-4c, cN0-3, HR-positive breast cancer. HR-positive disease was defined as tumors that were both ER-positive and progesterone receptor (PR)-positive. Patients who received neoadjuvant chemotherapy and/or neoadjuvant radiation therapy were excluded. We defined patients as receiving NET if endocrine therapy was initiated more than 30 days prior to their surgical intervention. The following variables were examined: patient age at diagnosis, sex, race, Charlson-Deyo comorbidity score, facility location, facility type, and county type (metro/urban/rural).
Statistical Analysis
The use of NET was evaluated over three time periods, defined as pre-Z1031 (2004) (2005) (2006) , during Z1031 (2007-2009), and post-Z1031 (2010-2012). Trends across these three time periods were evaluated using Cochran-Armitage trend tests. The associations of other demographic and clinical factors with the use of NET were evaluated using Chi-square tests for nominal variables, trend tests for ordinal variables, and two-sample ttests for continuous variables. The impact of NET on BCS was analyzed by comparing the proportion undergoing BCS between NET and primary surgery patients overall, and within clinical T-stage subgroups, using Chi-square tests. Adjusted analyses were performed using multivariable logistic regression. p Values \ 0.05 were considered statistically significant. Analysis was performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
RESULTS
We identified 85,884 patients C50 years of age with clinical tumor stage T2-4c HR (ER and PR)-positive breast cancer. Of these, 8612 (10.03 %) received neoadjuvant chemotherapy and were excluded from this analysis, leaving a cohort of 77,272 patients included in this study, of whom 2294 (3.0 %) received NET. The use of NET showed a small but statistically significant increase over time, from 2.7 % pre-Z1031 and during Z1031 to 3.2 % post-Z1031 (p \ 0.001). NET use varied by clinical T stage. For patients with cT2 tumors, NET use increased from 1.8 % pre-Z1031 and 2.0 % during Z1031 to 2.4 % post-Z1031 (p \ 0.001). In cT3 patients, NET use was 6.3 % pre-Z1031, 5.1 % during Z1031, and increased to 7.4 % in the post-Z1031 period (p = 0.02). No significant trend was observed among cT4a-c patients (p = 0.68) (Fig. 1) .
A comparison of patient characteristics, including patient demographics, Charlson-Deyo comorbidity score, facility location, facility type, and county type, between those receiving NET and those undergoing primary surgery is reported in Table 1 . Patients undergoing NET were older (mean age 71 years) compared with those undergoing primary surgery (mean age 67 years; p \ 0.001), and the use of NET was more common in females, with 3.0 % of women being treated with NET compared with 1.5 % of men (p = 0.001).
NET varied significantly by facility type (p \ 0.001) and was more frequently utilized in academic centers, where 4.2 % of patients received NET compared with cancer community programs (2.3 %) and comprehensive community cancer programs (2.5 %). Patients with more comorbidities had a higher use of NET, with 3.8 % of patients with a Charlson-Deyo score of 2 or more receiving NET compared with 2.9 % of patients with a CharlsonDeyo score of 0 or 1 (p = 0.01).
Comparisons of tumor characteristics, including tumor stage, grade, and type of breast surgery performed are reported in Table 2 . Clinical T-stage distribution was clinical T2 in 66,885 patients (86.6 %), clinical T3 in 7318 patients (9.5 %) and clinical T4a-c in 3069 patients (4.0 %). NET use increased with increasing T stage, from 2.2 % in cT2, 6.4 % in cT3, and 12.5 % in cT4 disease. NET was more commonly used in node-positive disease, with 2.7 % of clinically node-negative patients receiving NET compared with 4.0 % of patients with node-positive disease. NET use was highest in well-differentiated tumors (4.0 %) compared with moderately differentiated (3.0 %) and poorly differentiated tumors, which had the lowest rate (2.0 %).
In multivariable analysis, the post-Z1031 years demonstrated a significantly higher use of NET compared with pre-Z1031 [adjusted odds ratio (OR) 1.28, 95 % confidence interval (CI) 1.13-1.45; p \ 0.001] ( Table 3 ). The odds of NET also generally increased with age; patients aged 60-69, 70-79, and 80-89 years demonstrated adjusted ORs of 1.94 (95 % CI 1.70-2.22), 3.18 (95 % CI 2.79-3.63), and 3.14 (95 % CI 2.72-3.62), respectively, versus age 50-59 years (all p \ 0.001). Clinical T3 and T4a-c tumors were significantly more likely to undergo NET than cT2 tumors, with adjusted ORs of 3.08 (95 % CI 2.75-3.44) and 6.11 (95 % CI 5.38-6.94), as were clinically nodepositive patients (adjusted OR 1.28, 95 % CI 1.17-1.41; p \ 0.001). Higher-grade tumors were significantly less likely to be treated with NET. After adjusting for patient and clinical factors, a significant effect remained for academic/research programs versus community cancer programs (adjusted OR 2.14, 95 % CI 1.84-2.49; p \ 0.001) ( Table 3) .
Patients undergoing NET were significantly more likely to undergo BCS than patients treated with primary surgery (46.4 vs. 43.9 %; p = 0.02). This finding remained true after adjustment for patient, clinical, and facility factors in multivariable analysis, with an adjusted OR of 1.60 (95 % CI 1.46-1.75; p \ 0.001) when comparing odds of BCS between NET and primary surgery patients. Within each clinical T stage, the rates of BCS were higher in patients treated with NET compared with those undergoing primary surgery (Fig. 2) . The greatest increase was seen in cT2 disease (58.8 vs. 47.9 %; p \ 0.001). Strikingly, onequarter of patients with cT3 and cT4 disease treated with NET had BCS (26.2 vs. 15.0 % in cT3; 24.7 vs. 20.0 % in cT4a-c).
DISCUSSION
The use of NET has increased since the presentation and publication of the results of the ACOSOG Z1031 trial, from 2.7 % in the pre-Z1031 era (2004-2006) to 3.2 % post-Z1031 (2010-2012) among patients in the NCDB with an adjusted OR for post-Z1031 versus pre-Z1031 of 1.28 (95 % CI 1.13-1.45). The results from ACOSOG Z1031 demonstrated an overall BCS rate of 83 % in women who were considered marginal candidates for BCS at presentation and 51 % in women who were categorized as requiring mastectomy at initial presentation. 3 Data from the NCDB are consistent with this, showing that an increased number of patients receiving NET were able to undergo BCS compared with patients undergoing primary surgery across all T stages from cT2 to cT4. However, despite dramatic results reported from the Z1031 trial, the overall use of NET remained low through 2012. Some possible explanations for the slow adoption of NET include the fact that it takes time to disseminate clinical trial results and impact clinical practice, the responses seen with NET are slower than what is seen with neoadjuvant chemotherapy, and a complete response is less likely with NET.
The P024 trial was a randomized, double-blind, controlled trial that compared four months of neoadjuvant 1 The overall response rate was 55 % for letrozole and 33 % for tamoxifen (p \ 0.001), and the BCS rate was significantly higher with letrozole compared with tamoxifen (45 vs. 35 %, respectively; p = 0.022). The IMPACT trial was a phase III, randomized, multicenter trial comparing neoadjuvant tamoxifen, anastrozole, and the combination of tamoxifen and anastrozole in postmenopausal women with HR-positive invasive breast cancer. A total of 330 patients were randomized to receive neoadjuvant anastrozole, tamoxifen, or the combination of anastrozole and tamoxifen for 12 weeks. The overall response rate was 37 % for anastrozole, 36 % for tamoxifen, and 39 % for the combination. No significant difference was seen across the three arms. Of the 124 patients considered to require mastectomy at baseline, the conversion rate to BCS was 44 % for anastrozole, 31 % for tamoxifen, and 24 % for the combination. The improvement seen with anastrozole compared with tamoxifen was statistically significant. 2 The overall BCS rates after NET from the NCDB appear similar, with 59 % of cT2 tumors and 26.2 % of cT3 tumors treated with NET completing BCS; however, the extent of disease and surgical recommendation prior to NET is not known in this cohort.
It is important to identify those patients who would benefit the most from receiving NET. ER and PR status are obtained on all tumors, however not all ER-positive tumors are equally endocrine responsive. The PAM50 intrinsic subtype appears to be useful in identifying non-luminal tumors that are relatively endocrine-resistant despite strong ER positivity on immunohistochemistry. In Z1031, luminal A and luminal B tumors were highly endocrine therapy sensitive. 3 It has been suggested that tumors with both ER and PR positivity [50 % may be considered highly endocrine sensitive, whereas receptor positivity \50 % may indicate that tumors are less endocrine responsive. 4 Z1031 limited enrollment to patients with tumor Allred scores of 6 or higher based on the results of the letrozole P024 trial; 5 this criteria may be of clinical use when selecting appropriate patients for NET. We were not able to assess the degree of ER positivity or Allred score from the NCDB data, and therefore limited this NCDB study to patients with both ER-and PR-positive disease. The degree of quantitative ER expression may be a valuable selection factor, clinically, in predicting endocrine therapy responsiveness. [6] [7] [8] [9] NET has been historically used to treat patients with locally advanced breast cancer who were deemed unfit for chemotherapy because of advanced age and/or comorbidities. 10, 11 In our study, the mean age for patients receiving NET was slightly older at 71.1 years compared with 66.7 years in patients undergoing primary surgery; patients aged 70-89 years demonstrated a threefold increase in odds of NET compared with patients aged 50-59 years. This may reflect a reluctance to utilize When deciding to treat patients with neoadjuvant systemic therapy, the question of neoadjuvant chemotherapy versus NET should be considered. Low-grade tumors that are strongly ER-and PR-positive have lower rates of response to neoadjuvant chemotherapy than triple-negative or HER2-positive tumors; therefore, for low-grade strongly HR-positive disease, NET is the preferred approach. In this study, approximately 10 % of patients were excluded due to neoadjuvant chemotherapy. The proportion of HR? positive patients treated with neoadjuvant chemotherapy in this series is lower than seen, in general, for breast cancer, reflecting the hormone responsiveness of these tumors and less benefit of this tumor type from neoadjuvant chemotherapy.
Despite several strengths of this study, including its capture of data from multiple centers and large sample size, several limitations should be noted. Given the retrospective nature of the study, we cannot assess how the patients were selected to undergo NET. We also do not know the compliance or duration of the therapy. Whether the surgical recommendations were changed after completing treatment with NET is not captured in the NCDB. In addition, the NCDB lacks HER2 status information prior to 2010, and thus was not available during the earlier time periods of this study. Detailed histological information, such as the degree of quantitative ER or PR expression, is not available as the NCDB defines ER or PR status as positive for expression when [1 %. Thus, the cohort studied may include those patients who were unsuitable for NET, making the reported proportion of patients undergoing NET lower than if the proportion was calculated from patients deemed more suitable for NET.
CONCLUSIONS
Evaluation of the NCDB data showed a small but statistically significant increase in the use of NET in the US since the presentation and publication of ACOSOG Z1031, from 2. 
